Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 9,401–9,500 of 10,906
Vakhrusheva, A., Frolova, M. E., & Isaev, A. A. (2025) · Vaccines · doi:10.3390/vaccines13121187
“Most widely used vaccines, including Pfizer/BioNTech’s BNT162b2, Moderna’s mRNA-1273 [6,7], Oxford–AstraZeneca’s ChAdOx1 nCoV-19, and the Russian Sputnik V and single-dose version Sputnik Light [8–11], encode the full-length prefusion-stabilized Spike protein.”
Dynamics of the Immune Response in Hospitalized SARS-CoV-2-infected Cancer Patients
Aoki, M. N., Nardin, J. M., Huergo, L. F., Blanes, L., Morales, H. M. P., Fornazari, B., Conzentino, M. S., Migliorini, M. E. A., & Zanette, D. L. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2112693
Mahjabeen, N. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.4.2355
Injection site reactions after COVID-19 mRNA vaccination
Lian, B. S., Choo, K. J. L., Chong, C. J., et al. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021508
Pizzichetti, C., Latino, I., Virgilio, T., Capucetti, A., Chahine, K., Cascione, L., Moro, S. G., Bilato, G., Brügger, M., Kozarac, N., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106432
A Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection
Choi, S., Choi, Z., Ha, C., Lee, H.-J., & Kim, C. M. (2022) · 대한임상노인의학회지 · doi:10.15656/kjcg.2022.23.2.115
Yap, D. L., Mandell, C., & Behar, E. (2023) · Cognitive Therapy and Research · doi:10.1007/s10608-023-10391-8 · Cited by 1
Dhayfule, D., Wu, Y.-H., Ashyani, A., Li, M.-C., Tsai, C.-S., Chen, P., & Nordling, T. E. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11289-4
“Five vaccines reported efficacy of 100%, Sptutnik V [29], Coronavac [14], mRNA-1273 [16], BBIBP-CorV [20], Vero cells [20] and booster dose vaccine Soberana Plus [18].”
Forecasting the trend of COVID-19 under Imperfect Vaccination using the Homotopy Perturbation MethodPreprint
Ayoola, T. A., Alaje, A. I., Muhammad, H., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6564252/v1
Lipid nanoparticles as a tool to dissect dendritic cell maturation pathwaysPreprint
Janssens, S., Rennen, S., Bosteels, V., Nolf, C. D., Lil, K. V., Maréchal, S., Vetters, J., Velde, E. V. D., Fayazpour, F., Roelandt, R., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5461735/v1
Campos-Murguía, A., Román-Calleja, B. M., González-Regueiro, J. A., de León, I. H.-D., Solís-Ortega, A. A., Flores-García, N. C., García-Juárez, I., Ruiz‐Margáin, A., & Macías‐Rodríguez, R. U. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i33.5502
Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
Thookhamme, C., Navinpipat, M., Sasakul, A., Pattarakosol, P., Lertchaisataporn, K., Tawinprai, K., & Praditsuktavorn, P. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.2.107
Alexandre, M., Marlin, R., Bossevot, L., Cavarelli, M., Dereuddre‐Bosquet, N., Relouzat, F., Centlivre, M., Grand, R. L., Thiébaut, R., Lévy, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699647
American Covid: An Econometric Analysis of VariantsPreprint
McIntosh, J. (2022) · medRxiv · doi:10.1101/2022.06.09.22276226
Scherer, D., Honrath, S., Kurmann, J., Klipp, A., Brigger, F., & Leroux, J. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.70124
de Castro, A. A., de Assis, L. C., Appel, R. J. C., da Cunha, E. F. F., Nepovimová, E., Kuča, K., Ramalho, T. C., & Porta, F. A. L. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111046
Ramírez‐Ortiz, D., Moise, T., Alemohammad, S. Y., Aymat, M., Gray, A., Jean-Gilles, M. M., Sheehan, D. M., Ladner, R. A., & Trepka, M. J. (2025) · BMC Public Health · doi:10.1186/s12889-025-25017-9
“However, clinical trials including immunocompromised individuals have demonstrated the safety of COVID-19 vaccines [38–41].”
Muminov, M., Tsiferova, N. A., Pshenichnov, E., Ermatova, K., Charishnikova, O. S., Abdullaev, A. A., Levitskaya, Y., Akbarovna, D. D., Sandhya, M. V. S., Tomar, G. B., et al. (2024) · Vaccines · doi:10.3390/vaccines12121420
Assessing the effectiveness of vaccination strategies against respiratory pathogens
Abdullah, M. Y., Alanazi, F. M., Gandurah, S. F., Altufayif, D. A., Alghamdi, A. M., Halawani, O. A., Almudarhem, F. F., Al-Otaibe, R. I., Allathiqani, O. M., & Alasmari, A. A. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20250065
Fairlamb, M. S., Kumru, O. S., Hickey, J. M., et al. (2025) · doi:10.12688/verixiv.1767.1
Commentary on “Risk of venous thromboembolism after COVID‐19 vaccination”
Frère, C., & Salem, J. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15735
McEvoy, R., Hervol, J. R., Zhang, Y.-K., Wagner, E., Lindaas, A., Jiao, Y., Xu, S., Weintraub, E., Qian, L., Hong, V., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128460
Sukik, L., Paul, P., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag210
Battis, N., Ekstein, S. F., Cosky, E. E. P., et al. (2024) · Dermatitis · doi:10.1089/derm.2023.0379
Kisiel, J., Chojnicki, M., Kowala-Piaskowska, A. E., Wieczorowska–Tobis, K., Tobis, S., Religioni, U., Merks, P., & Neumann‐Podczaska, A. (2025) · Life · doi:10.3390/life15060879
Real-world impact of NVX-CoV2373 COVID-19 vaccine in immunocompromised individuals in South Korea
Gwak, E., Choe, S., Kim, K., Bolormaa, E., Gschwend, M. H., Fix, J., Vadivale, M., Rousculp, M. D., & Choe, Y. J. (2026) · BMC Public Health · doi:10.1186/s12889-026-26592-1 · Cited by 1
“IIC are often excluded from or vastly underrepresented in clinical trials of vaccines, and meta-analyses and systematic reviews of COVID-19 vaccine clinical trials have mostly focused on mRNA-based COVID-19 vaccines [9–12].”
Journal update monthly top five
Reynard, C., Prager, G., Oliver, G. J., Jafar, A. J. N., Naguib, M. P., Body, R. M., & Carley, S. D. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-212053 · Cited by 1
Clar, M., Walker, A., & Solomon, P. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_126-1
Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
Kim, M., Kim, B., Choi, J. P., Choi, N., Heo, J. Y., Choi, J. Y., Lee, J., & Kim, S. I. (2023) · Epidemiology and Health · doi:10.4178/epih.e2023090
Boratne, A. V., Kripa Angeline, A., Premalatha, M., & Pawar, S. J. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is-5.1142
Wang, J., Ai, J., Xiang, H., Zhang, Y., Hou, Z., Zhang, Q., Lv, J., Chen, S., Liu, C., Li, Q., et al. (2023) · Portal hypertension & cirrhosis · doi:10.1002/poh2.57
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0014
Manual de imunizações e sala de vacinas: a vacinação no contexto do Programa Nacional de Imunizações
(2021) · IMAC Editora eBooks · doi:10.22491/manual-imunizacoes · Cited by 1
Young, A. M. H., Neumann, B., Stoll, G. A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4124048
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.002.0004
Wong, K., Yuen, B. P., Kwok, C. H. Y., Lin, V. Y. C., Farrington, A. F., Cheung, H. W., Wong, W., & Ho, E. N. M. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70129 · Cited by 1
The Safety of COVID-19 Vaccine Accepted in Patients with Rheumatic Immune Diseases
朱, 芳. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134763
Modeling the role of latent period and vaccination in COVID-19 dynamics
Borah, P. B., Dehingia, K., Hınçal, E., Padder, A., & Sarmah, H. K. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00777-5 · Cited by 3
Tulisibaike, B., Yang, T.-Y., Gu, W., Liu, H., Wang, Y., Yang, J.-Q., Wang, T., Ding, S.-M., Cai, R.-X., Wang, Y., et al. (2026) · Vaccines · doi:10.3390/vaccines14060524
“In phase III trials, Comirnaty was effective in preventing COVID-19 among 95% of the recipients [42], while Spikevax efficacy was 94.1% [43].”
InfluentialJung, H. Y., Kim, T. H., Hadinoto, K., & Park, J.-W. (2024) · Tenside Surfactants Detergents · doi:10.1515/tsd-2024-2610
Decoding trends in mRNA vaccine research: A comprehensive bibliometric study
Zhang, C., Wang, Y., Peng, J., Wen, X., Zhang, Y., Li, K., Du, H., & Hu, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2355037 · Cited by 4
Wang, W., Wang, J., Jia, R., Martini, S., Liu, J., Huang, Y., Wang, F., Qi, X., & Fu, J. (2023) · Portal hypertension & cirrhosis · doi:10.1002/poh2.49
Dueker, K., Capozzola, T., Feng, Z., Lin, R. N., Hurtado, J., Bangaru, S., Yuan, M., Beutler, N., Garcia, E., He, W.-T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.700386
Liang, E. C., Onstad, L., Carpenter, P. A., Pergam, S. A., Flowers, M. E. D., Lee, S. J., & Liu, C. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.06.017
Micek, A., Diehl, K., Teuscher, M., Schaarschmidt, M., Sasama, B., Ohletz, J., Burbach, G. J., Kiecker, F., Hillen, U., Harth, W., et al. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14799_g
Lee, H., Hong, B., Lee, E., Park, J. Y., Jung, J., Kim, W. J., & Shin, J. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10803
Coronavirus disease 2019: fundamentals, chronology and vaccine evolution
Thirupathaiah, Y., & Chandel, A. K. (2021) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000289
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudyPreprint
Khan, Q. J., Bivona, C. R., Martin, G. A., Zhang, J., Liu, B., He, J., Li, K. H., Nelson, M., Williamson, S. K., Doolittle, G. C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3936503
Chanchlani, R., Shah, B. R., Bangdiwala, S. I., et al. (2023) · medRxiv · doi:10.1101/2023.12.08.23299660
Respuesta inmunológica a la vacunación y riesgo de COVID-19 en adultos con neoplasias hematológicas
Cortés, J. A., Nócua-Báez, L. C., Díaz‐Brochero, C., & Cuervo, S. I. (2023) · Revista chilena de infectología · doi:10.4067/s0716-10182023000300228 · Cited by 2
Zimmer, D. N., Schmid, F., & Settanni, G. (2026) · Small · doi:10.1002/smll.202513399 · Cited by 3
Soundararajan, V., Pawlowski, C., Lenehan, P. J., Puranik, A., Agarwal, V., Venkatakrishnan, A., Niesen, M. J. M., O’Horo, J. C., Badley, A. D., & Halamka, J. D. (2021) · Research Square · doi:10.21203/rs.3.rs-237155/v1
COVID-19 vaccines-related dermatological manifestations
Pathania, Y. S. (2025) · Cosmoderma · doi:10.25259/csdm_88_2025
Sinaei, R., Najafzadeh, M. J., Ghafari, S., Hosseininasab, A., Pardakhty, A., Dalfardi, B., Yousefi, M., Sinaei, A., Pezeshki, S., Sinaei, R., et al. (2024) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid-142157
Systematic Review and Meta‐Analysis of Emerging Viral Zoonotic Diseases, 2016–2026
Tao, P., Ying-an, Z., Wang, J., Cong, F., & Liao, M. (2026) · Transboundary and Emerging Diseases · doi:10.1155/tbed/9884191
Cheli, B., Bellavite, P., Foschi, R., Bagnato, A., Gregori, M., Trambusti, G., & Donzelli, A. (2026) · F1000Research · doi:10.12688/f1000research.181425.1
Psoriasis Biologics and the COVID-19 Pandemic: Lessons Learned
Hadeler, E. K., Hong, J. J., Mosca, M., Hakimi, M., & Bhutani, T. (2022) · Updates in clinical dermatology · doi:10.1007/978-3-030-92938-1_12
CHARACTERISTICS OF ADVERSE EVENTS OF CORONAVIRUS DISEASE 2019 VACCINES FIRST, SECOND AND BOOSTER
Probowati, W., Jayadi, T., & Rustam, B. M. (2023) · Berkala Ilmiah Kedokteran Duta Wacana · doi:10.21460/bikdw.v8i2.721
Toyonaga, H., Cheng, L., & Tanaka, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00982
A Universal, AI-based Design Framework for Efficient Manufacturing of mRNA TherapeuticsPreprint
Liao, K., Maccari, G., Ciano, G., Huber, R. G., von der Haar, T., Tham, C. Y., Ong, N. T. X., de Sessions, P. F., Saw, T. Y., Lim, T. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.09.710039
Mandal, D., Saeed, S., Mandal, P., Kaur, K. N., & Ganguly, N. K. (2025) · Discover Public Health · doi:10.1186/s12982-025-00487-9
Foundational public health education strengthens conditions for effective health policy
Viera, A. J., Nohria, R., & Vaughn, J. (2026) · Discover Public Health · doi:10.1186/s12982-026-02708-1
“Vaccination remains one of the most effective public health interventions, having prevented hundreds of millions of illnesses and hundreds of thousands of deaths in recent decades [5–8].”
Pongkulkiat, P., Foocharoen, C., Nanthapisal, S., Phanthanawiboon, S., Meesing, A., Suwannaroj, S., Mootsikapun, P., & Mahakkanukrauh, A. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2025-001631
Travel vaccination in senior travelers: current evidence, challenges, and prevention
Rossanese, A., & Tomasi, A. (2026) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-026-00315-1 · Cited by 1
“Available data show favorable safety and relevant immunogenicity in older adults for mRNA-1273 [37, 40], the chimpanzee adenoviral-vectored vaccine ChAdOx1 nCoV-19 [13], and MVC-COV1901 [41], while a booster strategy may also influence the immune response in this age group [13, 37].”
Hejran, A. B., Niazi, P., & Sangin, M. Y. (2026) · Frontiers in Virology · doi:10.3389/fviro.2026.1926007
36 Safety and Pharmacovigilance in Emergency Research Response
Teitelbaum, M., Atri, N., & Cahill, K. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_56
Milojevic-Ilic, M. (2023) · Medicinski pregled · doi:10.2298/mpns2308217m
Yoong, S. Q., Bhowmik, P., & Dutta, D. (2023) · medRxiv · doi:10.1101/2023.08.10.23293964
López, A. I. P., Ramal, S. L., Barrachina, S. S., et al. (2023) · Revista de Lactancia Materna · doi:10.14201/rlm.30761
Khonza, M. M., Saeed, Z., Jabeen, Z., Arab, W., Kakakhel, S., Yamin, M., Ghaith, M. M., Javed, A., Zohaib, A., & Abdulal, R. H. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1922523
“Recently, the use of mRNA vaccines in the COVID-19 pandemic highlighted their role as a safe and cheaper substitute for standard vaccine production technologies (Gote et al., 2023; Riaz et al., 2024).”
Development of donor specific antibodies after SARS-CoV-2 vaccination: What do we know so far?
Daoud, A., Soliman, K. M. M., Salas, M. A. P., et al. (2024) · World Journal of Meta-Analysis · doi:10.13105/wjma.v12.i2.91264
Thrombocytopenia as an Emerging Adverse Event Associated with COVID-19/SARS-CoV2 Vaccination
Welker, J. A., Crowe, A., & Hassan, W. (2022) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2022/v34i54b7239
Zheng, Y., Zheng, B., Gong, X., Pān, H., Jiang, C., Mao, S., Lin, S., Jin, B., Kong, D., Yao, Y., et al. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000154
Witczak, P. (2022) · Wydawnictwo Naukowe Instytutu na rzecz Kultury Prawnej Ordo Iuris eBooks · doi:10.37873/oipress.37.43
Chikasue, T., Kurata, S., Sumi, A., Matsuda, A., Tsubaki, F., Fujimoto, K., & Abe, T. (2022) · PubMed Central · doi:10.22038/aojnmb.2021.59883.1419 · Cited by 1
Khan, I., Ravindran, R. K., Kang, H., McReynolds, C. B., Sanghar, G. K., Chang, W. C., Ramasamy, S., Kolloli, A., Kumar, R., Subbian, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1987647/v1
Unveiling Fundamentals and Research Opportunities of mRNA Technology
Kumar, D., Singh, A., Kaviraj, S., & Singh, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-0896-3_5
Yan, L., Yi, J., Liu, D., Li, J., Baidoo, A. A. H., & Xie, L. (2025) · Vaccines · doi:10.3390/vaccines13090984
Impfstoffentwicklung zur Prävention von COVID-19 bei Jugendlichen
Augustin, M., Hallek, M. J., Nitschmann, S., et al. (2021) · Der Internist · doi:10.1007/s00108-021-01195-7
Evaluation of Side Effects Associated with COVID-19 Vaccines in Pregnant Women
Mirzaie, F., Badakhsh, M., Nasab, M. B., & Mousaei, Z. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.54
Sarı, O., & Tekin, K. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.21
Khalaileh, A., Imam, A., Jammal, A., Hakimian, D., Amer, J., Shafrir, A., Milgrom, Y., Massarwa, M., Hazou, W., Khader, M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000025
Hara, S., Arase, S., Suzuki, T., Mizogaki, I., Miyazaki, T., Kubara, K., Ida, Y., Kondo, K., Arai, K., Suzuki, Y., et al. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108488 · Cited by 2
Yang, Y., Song, T., Huang, K., Huang, H., Zhao, M., & Li, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091094
“…lipids that have reached clinical application include DLin-MC3-DMA (used in Onpattro), SM-102 (used in the Moderna COVID-19 vaccine), and ALC-0315 (used in the Pfizer–BioNTech COVID-19 vaccine), each with distinct performance profiles in terms of potency, tolerability, and biodistribution [25,26].”
Sung, M., Kim, Y. S., Cho, C. Y., Son, Y., Kim, D. W., & Lee, S. H. (2024) · Vaccines · doi:10.3390/vaccines12101190 · Cited by 2
Hart, D. (2021) · Medizinrecht · doi:10.1007/s00350-021-5944-5
Liu, M., Zhang, B., Pan, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4611767/v1
Domingo, J. R. C., Ocampo, A. M. M., Tan‐Lim, C. S. C., Dans, L. F., Dator, M. A., Alejandro, M. A. J. I., Paz, E., Gonzales, M. L. A., & Bagamasbad, P. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5367706
Pelayanan Kesehatan Pegawai Laboran Unusa Dalam Upaya Menambah Wawasan Serta Pencegahan Covid-19
Sari, N. D. K., & Nugraha, G. (2022) · Prosiding Seminar Nasional Pengabdian Kepada Masyarakat · doi:10.33086/snpm.v1i1.864
das Chagas, R. R., Freitas, H. R., & Cardozo, S. V. (2024) · medRxiv · doi:10.1101/2024.12.03.24318348
Streiber, M., Liu, N., Simon, L., Adermann, F., Bachmann, V., Hoeppener, S., Schubert, S., Werz, O., Lapinte, V., Morille, M., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5200072
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.